Eosinophilic Esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus that has rapidly transitioned from under-recognized to a major focus in gastroenterology. Driven by food allergens and characterized by eosinophilic infiltration of the esophageal lining, EoE leads to progressive esophageal dysfunction. The condition is now managed with a combination of diet, medication, and emerging biologics, reflecting a growing shift toward individualized,...
Chronic Spontaneous Urticaria (CSU) is a dermatologic condition defined by the recurrence of hives, angioedema, or both for more than six weeks, without any identifiable external trigger. Affecting approximately 0.5%–1% of the global population, CSU is more than a skin condition — it is a chronic inflammatory disease driven by mast cell dysregulation and autoimmunity. Recent advances in pathophysiology and biologic therapies are transforming how CSU is diagnosed and managed....
Alpha-1 Antitrypsin Deficiency (AATD) is a rare genetic condition increasingly recognized for its role in early-onset lung and liver disease. Once confused with common COPD, AATD is now becoming a focus of targeted respiratory care, thanks to growing awareness, improved diagnostics, and evolving therapeutic options. The condition highlights how personalized medicine can reshape outcomes in inherited disorders.
Request a sample copy of the CI report at:...
The mRNA Vaccine and Therapeutics Market is witnessing exceptional growth, driven by technological advancements, rising disease prevalence, and increasing government support for RNA-based treatments. From fighting COVID-19 to targeting cancer and rare diseases, mRNA is shaping the next generation of medicine.
To Get Free Sample Report: https://www.datamintelligence.com/download-sample/mrna-vaccine-and-therapeutics-market
Market Size and Forecast
As of 2023, the global mRNA vaccine and...
Warm Autoimmune Hemolytic Anemia (wAIHA) is a rare yet increasingly recognized hematologic disorder driven by immune system dysregulation. Once managed primarily with corticosteroids, wAIHA is now entering a new era, where precision therapies and immunomodulation are reshaping care and improving long-term outcomes.
Request a sample copy of the CI...
Stargardt disease, a rare genetic eye disorder, is emerging as a key focus in retinal therapeutics. With no approved cure yet available, this inherited form of macular degeneration primarily affects children and young adults, progressively reducing central vision. However, advancements in gene therapy, stem cell technology, and disease-modifying interventions are ushering in a new era of hope.
Request a sample copy of the CI report...
The Veterinary Pain Management drugs market is forecast to grow from approximately USD 2.5 billion in 2024 to USD 3.82 billion by 2030, registering a steady CAGR of 6.8%. The growth is fueled by increasing pet ownership, a rise in chronic conditions like osteoarthritis and cancer among animals, greater adoption of pet insurance, and the launch of advanced treatment options including monoclonal antibodies and laser therapy.
To Get Free Sample Report:...
Gaucher’s Disease, a rare lysosomal storage disorder, is entering a new era of targeted therapies and patient-centered treatment. No longer managed solely by biweekly enzyme replacement, the field is evolving with oral agents, precision diagnostics, and the promise of gene therapy. As clinical science advances, Gaucher’s Disease is emerging as a model for rare genetic disease innovation.
Request a sample copy of the CI report...
Gene Therapy Market Set to Expand to USD 29–55 Billion by 2033–2034
The Gene Therapy Market, valued at approximately USD 8–9 billion in 2024, is projected to grow at a compound annual growth rate (CAGR) of 18–20%, reaching between USD 29 and 55 billion by 2033–34. This dynamic expansion is driven by a growing pipeline of oncology and rare disease therapies, breakthroughs in vector technology, precision medicine tools, and increasing regulatory approvals.
To Get...
Radioligand therapy (RLT) combines tumor-specific ligands with radioisotopes to deliver highly targeted radiation to cancer cells with minimal impact on healthy tissues. Founded on a precision innovation model in hemophilia B, RLT is transforming the treatment of metastatic and refractory cancers. With recent clinical approvals and an expanding global pipeline, RLT promises sustained innovation and broader patient access.
Request a sample copy of this report at: ...
A comprehensive new analysis reveals the global Cerebral Palsy (CP) Treatment Market is expected to grow from $3.21 billion in 2022 to $4.28 billion by 2030, progressing at a compound annual growth rate (CAGR) of 3.7%.
This market is evolving rapidly as innovation in regenerative medicine, neurorehabilitation, digital therapy platforms, and supportive policy initiatives gain momentum across key global markets.
Sample Report : https://www.datamintelligence.com/download-sample/Cerebral...
The global theranostics market reached USD 1.8 billion in 2022 and is projected to grow to USD 4.2 billion by 2031, exhibiting a CAGR of 11.3% during the forecast period 2024–2031, driven by rising demand for personalized and precise medical treatments. Theranostics combines diagnostics and targeted therapy to tailor care based on individual disease profiles, leveraging molecular and genetic insights. This integrated approach enables physicians to make informed treatment decisions,...
Arabic
עברית
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek